1. Home
  2. MBWM vs SGP Comparison

MBWM vs SGP Comparison

Compare MBWM & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBWM

Mercantile Bank Corporation

SELL

Current Price

$60.21

Market Cap

1.1B

Sector

Finance

ML Signal

SELL

Logo SpyGlass Pharma Inc. Common Stock

SGP

SpyGlass Pharma Inc. Common Stock

SELL

Current Price

$31.76

Market Cap

1.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MBWM
SGP
Founded
1997
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
1997
2026

Fundamental Metrics

Financial Performance
Metric
MBWM
SGP
Price
$60.21
$31.76
Analyst Decision
Hold
Strong Buy
Analyst Count
6
6
Target Price
★ $64.17
$46.67
AVG Volume (30 Days)
99.0K
★ 106.3K
Earning Date
10-20-2026
11-11-2026
Dividend Yield
★ 2.64%
N/A
EPS Growth
★ 10.95
N/A
EPS
★ 4.21
N/A
Revenue
N/A
N/A
Revenue This Year
$16.34
N/A
Revenue Next Year
$7.39
N/A
P/E Ratio
$14.37
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$43.40
$17.06
52 Week High
$63.41
$39.92

Technical Indicators

Market Signals
Indicator
MBWM
SGP
Relative Strength Index (RSI) 49.24 49.15
Support Level $56.97 $23.55
Resistance Level $62.64 $39.92
Average True Range (ATR) 1.40 2.53
MACD -0.03 -0.33
Stochastic Oscillator 16.29 18.40

Price Performance

Historical Comparison
MBWM
SGP

About MBWM Mercantile Bank Corporation

Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.

About SGP SpyGlass Pharma Inc. Common Stock

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

Share on Social Networks: